CHARLES RIVER LABORATORIES INTERNATIONAL, INC. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Charles River reported Q2 2026 revenue of $1.00B (down 2.7% YoY reported, +0.1% organic). Non-GAAP EPS of $3.02 (down 3.2% YoY) despite raising full-year 2026 guidance by 150 bps organic growth and $0.25 non-GAAP EPS at midpoint. Key drivers: completed divestitures of CDMO, Cell Solutions, and European Discovery Services sites (net loss $181.7M YTD); $100M stock repurchase in Q2 at $174/share; strongest book-to-bill in ~4 years in DSA segment; launched AI digital pathology solution and new partnerships with Eli Lilly and Arovella.
Why this rating
Organic growth stabilization and guidance raise are modest positives; divestitures and losses ($181.7M net) reduce near-term earnings despite portfolio strengthening. Meaningful but not trajectory-altering for $7.3B company.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.